Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: A prospective, randomized, controlled clinical trial

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Ge, Yongchun ^a   Xie, Honglang ^a   Li, Shijun ^a   Jin, Bo ^a   Hou, Jinhua ^a   Zhang, Haitao ^a   Shi, Mingjun ^a   Liu, Zhihong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Angiotensin II receptor blocker (ARB); Diabetic nephropathy; Proteinuria; Tripterygium wilfordii Hook F (TwHF); Type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLANT EXTRACT; TRIPTERYGIUM WILFORDII HOOK F EXTRACT; UNCLASSIFIED DRUG; VALSARTAN; TETRAZOLE DERIVATIVE; VALINE;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DERMATITIS; DIABETIC NEPHROPATHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; LEUKOCYTE COUNT; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; TRIPTERYGIUM WILFORDII; TRIPTERYGIUM WILFORDII HOOK F; VOMITING; AGED; ANALOGS AND DERIVATIVES; CHEMISTRY; DIABETIC NEPHROPATHIES; DISEASE COURSE; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PHYTOTHERAPY; TREATMENT OUTCOME; TRIPTERYGIUM;

ADULT; AGED; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; PROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME; TRIPTERYGIUM; VALINE;

EID: 84878362911     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-134     Document Type: Article

References (36)

1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, China National Diabetes and Metabolic Disorders Study Group Prevalence of diabetes among Men and women in China. N Engl J Med 2010, 362:1090-1101. China National Diabetes and Metabolic Disorders Study Group.
2. Jin B, Liu ZH, Ge YC, Xie HL, Wang SF, Fu YJ, Li LS. Changes of epidemiologic character in patients with diabetic nephropathy received renal biopsy. Chin J Nephrol Dial and Transplant 2009, 18:133-139. Chinese.
3. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997, 51:2-15.
4. Yu HT. Progression of chronic renal failure. Arch Intern Med 2003, 153:1417-1429.
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. RENAAL Study Investigators.
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group Renoprotective effects of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860. Collaborative Study Group.
7. Liu ZH, Li SH, Wu Y, Zuo K, Wang B, Zeng CH, Li LS. Treatment of membranous nephropathy with tripterygium wilfordii and steroid: a prospective randomized control trial. Chin J Nephrol Dial and Transplant 2009, 18:303-309. Chinese.
8. Ji SM, Wang QW, Chen JS, Sha GZ, Liu ZH, Li LS. Clinical trial of Tripterygium wilfordii Hook F. in human kidney transplantation in China. Transplant Proc 2006, 38:1274-1279.
9. Liu H, Liu ZH, Chen ZH, Yang JW, Li LS. Triptolide: a potent inhibitor of NF-ΚB in T-lymphocytes. Acta Pharmacol Sin 2000, 21:782-786.
10. Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, Kivitz A, Sherrer Y, Pucino F, Csako G. Comparison of Triterygium wilfordii Hook F versus Sulfasalazine in the treatment of Rheumatoid Arthritis: a randomized trial. Ann Intern Med 2009, 151:229-240.
11. Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS, Liu ZH. Triptolide protects podocytes from puromycinaminonucleoside induced injury in vivo and in vitro. Kidney Int 2008, 74:596-612.
12. Chen ZH, Qin WS, Zeng CH, Zheng CX, Hong YM, Lu YZ, Li LS, Liu ZH. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int 2010, 77:974-988.
13. Gao Q, Shen W, Qin W, Zheng C, Zhang M, Zeng C, Wang S, Wang J, Zhu X, Liu Z. Treatment of obese db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant 2010, 25:3539-3547.
14. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med 2008, 358:2433-2446. AVOID Study Investigators.
15. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28(1):164-176.
16. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis 2010, 4(2):128-132.
17. Bartels H, Böhmer M, Heierli C. Serum creatinine determination without protein precipitation. Clin Chim Acta 1972, 37:193-197.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999, 130:461-470.
19. Rohlfing CL, Little RR, Wiedmeyer HM, England JD, Madsen R, Harris MI, Flegal KM, Eberhardt MS, Goldstein DE. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care 2000, 23:187-191.
20. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of diabetic nephropathy during antihypertention treatment. Diabetologia 1994, 37:511-516.
21. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int 1994, 45:S150-S155.
22. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19:433-442.
23. Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O, Fernandez-Vizarra P, Mallavia B, Flores C, Sanz A, Blanco J, Mezzano S, Ortiz A. Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol 2010, 21:763-772.
24. Su J, Li SJ, Chen ZH, Zeng CH, Zhou H, Li LS, Liu ZH. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker. Diabetes Res Clin Pract 2010, 87(2):167-175.
25. Zhu WW, Chen HP, Ge YC, Xie HL, Zeng CH, Li LS, Liu ZH. Ultrastructural changes in the glomerular filtration barrier and occurrence of proteinuria in Chinese patients with type 2 diabetic nephropathy. Diabetes Res Clin Pract 2009, 86:199-207.
26. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
27. Weidmann P, Boehlen LM, de Courten M. Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993, 8:582-584.
28. Hamilton RA, Kane MP, Demers J. Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: a meta-analysis. Pharmacotherapy 2003, 23:909-915.
29. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006, 47:699-705.
30. Wang G, Lai FM, Lai KB, Chow KM, Kwan BC, Li PK, Szeto CC. Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker. Eur J Endocrinol 2008, 158:317-322.
31. Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 2010, 332:1072-1080.
32. Wu Y, Cui J, Bao X, Chan S, Young DO, Liu D, Shen P. Triptolide attenuate oxidative stress, NF-kB activation and multiple cytokine gene expression in murine peritoneal macrophage. Int J Mol Med 2006, 17:141-150.
33. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD. Development and progression of renal disease in pima Indians with non-insulin-dependent diabetes mellitus. Diabetic renal disease study group. N Engl J Med 1996, 335:1636-1642.
34. Zhang Y, Jiang Z, Xue M, Zhang S, Wang Y, Zhang L. Toxicogenomic analysis of the gene expression changes in rat liver after a 28-day oral Tripterygium wilfordii multiglycoside exposure. J Ethnopharmacol 2012, 141:170-177.
35. Yao J, Jiang Z, Duan W, Huang J, Zhang L, Hu L, He L, Li F, Xiao Y, Shu B, Liu C. Involvement of mitochondrial pathway in triptolide-induced cytotoxicity in human normal liver L-02 cells. Biol Pharm Bull 2008, 31:592-597.
36. Pyatt DW, Yang Y, Mehos B, Le A, Stillman W, Irons RD. Hematotoxicity of the Chinese herbal medicine tripterygium wilfordii hook f in CD34-positive human bone marrow cells. Mol Pharmacol 2000, 57:512-518.